[1] 中华医学会心血管病学分会,中华医学会心电生理和起博分会,
中国医师协会心律学专业委员会,等.非瓣膜病心房颤动患者新
型口服抗凝药的应用中国专家共识[J].中华心律失常杂志,2014,
18(5):321-329.
[2] Beasley BN, Unger EF,Temple R. Anticoagulant options-why the FDA approved a higher but not a lower dose of
dabigatran [J]. N Engl J Med,2011,364(19):1788-1790.
[3] Verma A, Cairns JA, Mitchell LB,et al. 2014 focused
update of the Canadian cardiovascular society guidenlines
for the management of atrial fibrillation [J]. Can J Cardiol,
2014,30(10):1114-1130.
[4] 中华心血管病学杂志血栓循证工作组.非瓣膜病心房颤动患者采
用新型口服抗凝中专家建议[J].中华心血管病杂志,2014,42(5):
362.
[5] Paikin JS, Haroun MJ,Eikeiboom JM, et al. Dabigatran
for stroke prevention in atrial fibrillation: the RE-LY trail
[J]. Expert Rev Cardiovasc Ther, 2011,9(3):279-286.
[6] Connlly SJ, Ezekowitz MD,Yusuf S, et al. Dabigatran
versus warfarin in patients with atrial fibrillation [J]. N
Engl J Med,2009,361(12):1139-1151.
[7] Southworth MR, Reinchman ME, Unger EF. Dabigatran
and postmarketing reports of bleeding [J]. N Engl J Med,
2013,368(14):1272-1274.
[8] 倪铭,方阅,李琴,等.达比加群酯相关致命性出血-病例报告及文
献回顾[J].医院药学,2019,2(17):273-276.
[9] Zhou W, Schwarting S, Illanes S,et al. Hemostatic ther-apy in experimental intracerebral hemorrhage associated
with the direct thrombin inhibitor dabigatran [J]. Stroke,
2011,42(12):3594-3599.
[10] 彭卫珍,陈华,孔令春.双氯芬酸钠致不良反应46例分析[J].医药
导报杂志,2012,31(3):392-394.